Phibro Animal Health Corporation (NASDAQ:PAHC – Free Report) – Stock analysts at Zacks Research boosted their Q3 2026 earnings per share (EPS) estimates for Phibro Animal Health in a research note issued to investors on Friday, September 26th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.69 for the quarter, up from their prior estimate of $0.66. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.95 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q1 2027 earnings at $0.65 EPS, Q3 2027 earnings at $0.63 EPS and FY2027 earnings at $2.55 EPS.
Get Phibro Animal Health alerts:
A number of other analysts have also commented on PAHC. Bank of America lifted their price target on Phibro Animal Health from $19.00 to $27.00 and gave the stock an “underperform” rating in a report on Friday, August 29th. JPMorgan Chase & Co. raised Phibro Animal Health from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $25.00 to $35.00 in a research report on Monday, July 7th. Morgan Stanley set a $34.00 target price on Phibro Animal Health in a research report on Thursday, August 28th. BNP Paribas Exane raised Phibro Animal Health from an “underperform” rating to a “neutral” rating and set a $24.00 target price for the company in a research report on Monday, June 16th. Finally, BNP Paribas raised Phibro Animal Health to a “hold” rating in a research report on Monday, June 16th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $28.40.
Check Out Our Latest Stock Analysis on PAHC
Phibro Animal Health Stock Performance
Shares of Phibro Animal Health stock opened at $39.15 on Monday. The business’s fifty day simple moving average is $33.87 and its 200 day simple moving average is $26.79. The firm has a market capitalization of $1.59 billion, a P/E ratio of 33.18, a price-to-earnings-growth ratio of 1.15 and a beta of 0.88. Phibro Animal Health has a 12 month low of $16.16 and a 12 month high of $41.57. The company has a current ratio of 2.76, a quick ratio of 1.25 and a debt-to-equity ratio of 2.46.
Phibro Animal Health (NASDAQ:PAHC – Get Free Report) last issued its quarterly earnings results on Wednesday, August 27th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.05. The business had revenue of $378.70 million for the quarter, compared to analyst estimates of $362.24 million. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS.
Phibro Animal Health Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Wednesday, September 24th. Stockholders of record on Wednesday, September 3rd were given a $0.12 dividend. The ex-dividend date was Wednesday, September 3rd. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. Phibro Animal Health’s payout ratio is 40.68%.
Insider Buying and Selling at Phibro Animal Health
In other news, CEO Jack Bendheim sold 14,080 shares of Phibro Animal Health stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $40.33, for a total value of $567,846.40. Following the completion of the transaction, the chief executive officer directly owned 45,400 shares in the company, valued at approximately $1,830,982. The trade was a 23.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 24,622 shares of company stock valued at $995,893 in the last three months. 50.13% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Phibro Animal Health
Hedge funds have recently made changes to their positions in the stock. Nuveen LLC purchased a new position in Phibro Animal Health during the first quarter worth about $10,312,000. Invesco Ltd. grew its position in Phibro Animal Health by 92.3% during the first quarter. Invesco Ltd. now owns 387,739 shares of the company’s stock worth $8,282,000 after buying an additional 186,087 shares in the last quarter. Ranger Investment Management L.P. grew its position in Phibro Animal Health by 101.1% during the second quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock worth $9,143,000 after buying an additional 179,975 shares in the last quarter. Axecap Investments LLC purchased a new position in Phibro Animal Health during the first quarter worth about $3,696,000. Finally, Millennium Management LLC grew its position in Phibro Animal Health by 74.3% during the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after buying an additional 154,281 shares in the last quarter. 99.34% of the stock is currently owned by hedge funds and other institutional investors.
Phibro Animal Health Company Profile
(Get Free Report)
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
Further Reading
Five stocks we like better than Phibro Animal Health
Best ESG Stocks: 11 Best Stocks for ESG Investing
Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300
What is a Dividend King?
Cathie Wood Buys Alibaba and Baidu: Momentum or More Value Ahead?
Technology Stocks Explained: Here’s What to Know About Tech
This ETF Weeds Out Small-Cap Underperformers